Prostate Cancer

An Overview of the Prostate Cancer Treatment Landscape

March 9th 2022, 2:00pm


A comprehensive review of the therapeutic classes available for patients with prostate cancer.

Correlation Between Prostate Cancer and Cardiovascular Disease

March 2nd 2022, 2:20pm


Shared insight on the correlation between prostate cancer and cardiovascular disease, with a focus on the attributes that increase a patient’s risk.

Prostate Cancer’s Impact on Economy and Life

March 2nd 2022, 2:00pm


A broad look at the economic burden of prostate cancer and outlook in regard to survival within the current treatment landscape.

Understanding the Clinical Burden of Prostate Cancer

December 20th 2021, 5:00pm


Expert perspectives on prostate cancer with deference to clinical presentations, diagnosis, and prognosis.

Experts Discuss PARP Inhibition in Prostate and Ovarian Cancers

February 15th 2021, 1:00pm


Experts in gynecologic oncology and genitourinary oncology discuss the current state of PARP inhibitors in prostate and ovarian cancers.

Dr Ashley Ross on Genomic Testing Patients Post Prostatectomy

February 13th 2021, 2:00pm


Ashley Ross, MD, PhD, urologist and associate professor at the Northwestern University Feinberg School of Medicine provides insight into genomic testing in postprostatectomy patients.

Bayer, Orion Announce Expansion of Nubeqa Development Program

February 9th 2021, 1:37pm


Bayer and Orion corporation today announced the upcoming expansion of the global clinical development program for darolutamide (Nubeqa), an oral androgen receptor inhibitor for patients with prostate cancer.

MRI and Targeted Biopsy as Accurate as Current Standard for Prostate Cancer Diagnosis

February 5th 2021, 10:00pm


Results from the phase 3 PRECISE trial showed that MRI with targeted biopsies matched or exceeded the accuracy of the current standard for detecting clinically significant prostate cancer.

Dr Ashley Ross on the Potential for Targeted Therapies Earlier in Prostate Cancer Treatment

February 3rd 2021, 5:50pm


Ashley Ross, MD, urologist and associate professor at the Northwestern University Feinberg School of Medicine, gives insight on the potential for PARP inhibitors in earlier disease settings for prostate cancer.

Study Finds Shorter Radiation Regimen Safe, Effective for Advanced Prostate Cancer

January 30th 2021, 3:00pm


Shortening a traditional 45-day course of radiation therapy to 5 days of stereotactic body radiotherapy for patients with advanced, high-risk prostate cancer is safe and effective, a study from UCLA Jonsson Comprehensive Cancer Center found.